Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.

Author(s): Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM

Affiliation(s): Department of Haematology and Faculty Division, Ulleval University Hospital Trust, Oslo, Norway. a.l.eilertsen@medisin.uio.no

Publication date & source: 2008-05, BJOG., 115(6):773-9. Epub 2008 Mar 19.

Publication type: Randomized Controlled Trial

OBJECTIVE: To evaluate impact of different postmenopausal hormone therapy (HT) regimens and raloxifene on mammographic breast density. DESIGN: Open, randomised, comparative clinical trial. SETTING: Women were recruited through local newspapers and posters. They were examined at the Departments of Haematology, Gynaecology, and Radiology in a University Hospital. POPULATION: A total of 202 healthy postmenopausal women between the age of 45 and 65 years. METHODS: Women were randomly assigned to receive daily treatment for 12 weeks with tablets containing low-dose HT containing 1 mg 17 beta-estradiol + 0.5 mg norethisterone acetate (NETA) (n = 50), conventional-dose HT containing 2 mg 17 beta-estradiol and 1 mg NETA (n = 50), 2.5 mg tibolone (n = 51), or 60 mg raloxifene (n = 51). Mammographic density was determined at baseline and after 12 weeks by an automated technique in full-field digital mammograms. MAIN OUTCOME MEASURES: Mammographic density was expressed as volumetric breast density estimations. RESULTS: Mammographic breast density increased significantly and to a similar degree in both the conventional- and low-dose HT groups. A small reduction in mammographic breast density was seen in the raloxifene group, whereas those allocated to tibolone treatment only showed minor changes. CONCLUSIONS: Our findings demonstrated a significant difference in impact on mammographic breast density between the regimens. Although these results indicate a differential effect of these regimens on breast tissue, the relation to breast cancer risk remains unresolved.